Elicera's collaboration with LifeSci Consulting is a long-term investment that follows an increase in third-party interest to initiate potential collaboration dialogues with Elicera around its iTANK platform and certain programs under development.

"We are pleased to have seen interest in collaborations rise after proof-of-concept data for the iTANK platform was published in Nature Biomedical Engineering (https://www.elicera.com/press-releases/elicera-therapeutics-publishes-scientific-article-in-nature-biomedical-engineering-on-the-itank-platform-and-data-indicating-its-universal-compatibility-with-other-car-t-cell-therapies) last year. Securing licensing agreements and a variety of collaborations for iTANK is an essential part of Elicera's business strategy and we believe it is in our shareholders' best interest that the company explore different partnering options together with a leading life science transaction advisory firm such as LifeSci Consulting. While completion of any transactions is not assured, we look forward to beginning our collaboration with LifeSci Consulting and exploring different partnering alternatives together with them," says Jamal El-Mosleh, CEO of Elicera Therapeutics.

"Elicera is developing state-of-the-art technology to solve immune challenges in the oncology space and Elicera's next generation iTANK platform and ongoing programs have the potential to take us to the next frontier of cancer treatment. This collaboration will accelerate Elicera's ability to find optimal partners to generate long-term value for patients and shareholders. With 5,000+ global industry contacts and $8B total deal value, our team is ideally positioned to provide Elicera with impactful strategic counsel to support optimum strategic transactions. We are impressed by the leadership and expertise at Elicera and look forward to our exciting journey ahead", said Cristiano Musso, Partner, Head of Europe of LifeSci Consulting.